The device can be used in conjunction with standard-of-care assessment in a clinical setting or hospital. Credit: Lee Charlie/Shutterstock.com.

Swiss medical device start-up Acorai has received breakthrough device designation from the US Food and Drug Administration (FDA) for its heart monitor.

The intracardiac pressure monitor (IPCM) is intended to non-invasively estimate mean pulmonary artery pressure, diastolic pulmonary artery pressure and systolic pulmonary artery pressure in patients with Stage C heart failure (HF), who were recommended for haemodynamic monitoring.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Claimed to be the first of its kind, the IPCM device leverages a proprietary machine-learning system and patented hardware technology.

It is designed as a companion test for qualified healthcare professionals.

For detecting haemodynamic congestion and supporting HF personalised treatment, the device can be used in conjunction with standard-of-care assessment in a clinical setting or hospital.

Acorai chief operating officer and co-founder Kasper Bourdette said: “Receiving breakthrough designation is a massive inflection point in our device development journey, and we are thrilled about the decision.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Preliminary data from a Swedish pilot study involving 281 out of 400 patients has supported the breakthrough device application.

Acorai has obtained ethics approval in five countries, including the US, to conduct a larger study involving 1,200 patients.

This study aims to ensure that the device is generalisable across a global heart failure population.

Acorai CEO and co-founder Filip Peters said: “We could not be more delighted with the decision from the FDA, and it constitutes a huge milestone for us as a company. Congratulations to the entire Acorai team who have worked hard to enable this.”